ARTICLE | Clinical News
Inconclusive FSAD study for IC351
June 15, 2001 7:00 AM UTC
Lilly Icos, a joint venture between Eli Lilly (LLY) and Icos (ICOS), announced after market close that IC351 showed no conclusive treatment effect compared to placebo in a worldwide double-blind Phase...